Objective: Adipose tissue plays a role in the novel coronavirus disease 2019 (COVID-19). Epicardial adipose tissue (EAT), a unique visceral fat, presents with high degree of inflammation in severe COVID-19 disease. Whether and how adipose tissue may respond to the COVID-19 therapies is unknown. Methods: We retrospectively analyzed the difference in computed tomography (CT) measured EAT and subcutaneous (SAT) attenuation, defined as mean attenuation expressed in Hounsfield units (HU), in 72 patients [mean±SD age was 59.6±12.4 years, 50 (69%) were men] at the hospital admission for COVID-19 and 99 days [IQR (71-129)] after discharge. Results: At the admission, EAT HU was significantly correlated with blood glucose levels, interleukin 6 , troponin T levels and waist circumference. EAT HU decreased from -87.21±16.18 to -100.0±11 (p<0.001) whereas SAT HU did not change (-110.21±12.1 to -111.11±27.82, p=0.78) after therapy. Changes in EAT HU (expressed as ∆) significantly correlated with dexamethasone therapy (r= - 0.46, p= 0.006), and when dexamethasone was combined with tocilizumab (r= -0.24, p=0.04). Conclusions: Dexamethasone therapy was associated with significant reduction of EAT inflammation in COVID-19 patients, whereas SAT showed no changes. Anti-inflammatory therapies targeting visceral fat may be helpful in COVID-19 diseases.
Epicardial fat inflammation response to COVID-19 therapies / G. Iacobellis, A.E. Malavazos, S. Basilico, S. Tresoldi, R.F. Rinaldo, C. Dubini, G. Capitanio, F. Serpi, S. Schiaffino, O.A. Oliva, M. Cariati, L. Morricone, S. Centanni, F. Sardanelli, M. Carruba, M.M. Corsi Romanelli, F. Secchi. - In: OBESITY. - ISSN 1930-7381. - (2021). [Epub ahead of print] [10.1002/oby.23232]
Epicardial fat inflammation response to COVID-19 therapies
A.E. MalavazosPrimo
;S. Basilico;S. Tresoldi;R.F. Rinaldo;F. Serpi;O.A. Oliva;S. Centanni;F. Sardanelli;M. Carruba;M.M. Corsi Romanelli;F. SecchiUltimo
2021
Abstract
Objective: Adipose tissue plays a role in the novel coronavirus disease 2019 (COVID-19). Epicardial adipose tissue (EAT), a unique visceral fat, presents with high degree of inflammation in severe COVID-19 disease. Whether and how adipose tissue may respond to the COVID-19 therapies is unknown. Methods: We retrospectively analyzed the difference in computed tomography (CT) measured EAT and subcutaneous (SAT) attenuation, defined as mean attenuation expressed in Hounsfield units (HU), in 72 patients [mean±SD age was 59.6±12.4 years, 50 (69%) were men] at the hospital admission for COVID-19 and 99 days [IQR (71-129)] after discharge. Results: At the admission, EAT HU was significantly correlated with blood glucose levels, interleukin 6 , troponin T levels and waist circumference. EAT HU decreased from -87.21±16.18 to -100.0±11 (p<0.001) whereas SAT HU did not change (-110.21±12.1 to -111.11±27.82, p=0.78) after therapy. Changes in EAT HU (expressed as ∆) significantly correlated with dexamethasone therapy (r= - 0.46, p= 0.006), and when dexamethasone was combined with tocilizumab (r= -0.24, p=0.04). Conclusions: Dexamethasone therapy was associated with significant reduction of EAT inflammation in COVID-19 patients, whereas SAT showed no changes. Anti-inflammatory therapies targeting visceral fat may be helpful in COVID-19 diseases.File | Dimensione | Formato | |
---|---|---|---|
oby.23232.pdf
Open Access dal 25/05/2022
Tipologia:
Post-print, accepted manuscript ecc. (versione accettata dall'editore)
Dimensione
694.84 kB
Formato
Adobe PDF
|
694.84 kB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.